Scarica l'app Stockscreener
261.23
0.16%
0.42
Dopo l'orario di chiusura:
257.00
-4.23
-1.62%
Ascendis Pharma A S Borsa (ASND) Ultime notizie
Ascendis Pharma (NASDAQ: ASND) Issues 29,380 Employee Warrants at $270.09 Exercise Price - Kalkine Media
Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock - Benzinga
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy - Investing.com
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com India
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data - Investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data By Investing.com - Investing.com India
BMO reiterates Ascendis Pharma stock rating on infant trial data - Investing.com
Early infant trial hints at spine and growth gains, Ascendis Pharma (NASDAQ: ASND) says - Stock Titan
Ascendis Pharma SVP & Pao Sold Shares Worth Over $810K - TradingView
Ascendis Pharma (ASND) officer cashes 3K warrants, sells matching shares - Stock Titan
Ascendis Pharma (NASDAQ: ASND) prices new employee warrants at $270.09 - Stock Titan
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 - globenewswire.com
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors - ChartMill
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Ascendis Pharma (NASDAQ: ASND) officer lines up 3,000-ADS sale for 2026 - Stock Titan
Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026 - The Clinical Trial Vanguard
Ascendis Pharma A/S Trade Ideas — HAM:A710 - TradingView
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - The Manila Times
Ascendis Pharma to Present Sentinel Cohort Data from reACHin Trial of TransCon CNP at ESPE 2026 - Quiver Quantitative
Ascendis Pharma A/S (ASND) Stock Analysis: Unveiling a 16.35% Potential Upside for Investors - DirectorsTalk Interviews
Ascendis Pharma (ASND) Could Be 14% Undervalued Following Yorvipath Reimbursement Progress - simplywall.st
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312 - Moomoo
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus - Yahoo Finance
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Yahoo Finance
Ascendis Pharma Director Lars Holtug Executes Sale of 236 Shares at $264.13 Each - Kalkine Media
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND) - The Globe and Mail
Ascendis Pharma (ASND) director to sell shares for taxes - Stock Titan
Oppenheimer Adjusts Price Target on Ascendis Pharma to $312 From $304, Maintains Outperform Rating - marketscreener.com
Stifel Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $326 - Moomoo
Ascendis Pharma A/S (ASND) Institutional Ownership 2026 - MarketBeat
Oppenheimer raises Ascendis Pharma stock price target on settlement By Investing.com - Investing.com Australia
BioMarin To Get Royalties From Ascendis Under IP Settlement - Law360
Oppenheimer raises Ascendis Pharma stock price target on settlement - Investing.com
BofA cuts Ascendis Pharma stock price target on settlement impact By Investing.com - Investing.com South Africa
BioMarin announces global settlement with Ascendis - The Pharma Letter
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $273 to $344 - Moomoo
Ascendis Pharma (ASND) Clears Yuviwel Patent Fight With Global Licensing Deal - simplywall.st
BofA cuts Ascendis Pharma stock price target on settlement impact - Investing.com
Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
Ascendis Pharma settles patent dispute with US-based Biomarin - medwatch.com
Ascendis Pharma ASND Draws Bullish Targets After Q2 Earnings Surge - timothysykes.com
Ascendis Pharma (NASDAQ: ASND) strikes global YUVIWEL settlement with BioMarin - stocktitan.net
Ascendis Pharma A/S and Biomarin Pharmaceutical Inc. Enter Binding Term Sheet for Global Settlement and License Agreement Related to Yuviwel and Navepegritide-Related Products - marketscreener.com
Ascendis to pay 20% Yuviwel royalties in patent settlement with BioMarin - Fierce Pharma
Why Ascendis Pharma (ASND) Stock Is Up Today - Quiver Quantitative
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis - BioSpace
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday - Benzinga
Jefferies lowers Ascendis Pharma stock price target on settlement - Investing.com
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes - finance.yahoo.com
BioMarin Licenses CNP Program to Ascendis With 20%/18% Royalties, Ends Patent Disputes - TradingView
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) - Yahoo Finance
Ascendis Pharma A/S (ASND): Investor Outlook Reveals a Promising 27% Upside Potential in Biotech - DirectorsTalk Interviews
ASND Stock Climbs As Analysts Chase Ascendis Pharma Rally - StocksToTrade
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - PR Newswire
Ascendis Pharma (ASND) Shares Week 104 Data As FDA Clears Pediatric Achondroplasia Drug - simplywall.st
H.C. Wainwright initiates Ascendis Pharma stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Ascendis Pharma stock coverage with buy rating By Investing.com - Investing.com India
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):